DBV Technologies S.A. - Asset Resilience Ratio
DBV Technologies S.A. (DBV) has an Asset Resilience Ratio of 51.48% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read DBV total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2007–2024)
This chart shows how DBV Technologies S.A.'s Asset Resilience Ratio has changed over time. See DBV Technologies S.A. (DBV) shareholders funds for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down DBV Technologies S.A.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see DBV market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €73.84 Million | 51.48% |
| Short-term Investments | €0.00 | 0% |
| Total Liquid Assets | €73.84 Million | 51.48% |
Asset Resilience Insights
- Very High Liquidity: DBV Technologies S.A. maintains exceptional liquid asset reserves at 51.48% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
DBV Technologies S.A. Industry Peers by Asset Resilience Ratio
Compare DBV Technologies S.A.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229 |
Biotechnology | 0.21% |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333 |
Biotechnology | 35.96% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.48% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 70.49% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
Annual Asset Resilience Ratio for DBV Technologies S.A. (2007–2024)
The table below shows the annual Asset Resilience Ratio data for DBV Technologies S.A..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | €0.00 ≈ $0.00 |
€65.66 Million ≈ $76.76 Million |
-- |
| 2023-12-31 | 64.18% | €117.44 Million ≈ $137.30 Million |
€182.99 Million ≈ $213.93 Million |
-8.47pp |
| 2022-12-31 | 72.65% | €179.09 Million ≈ $209.38 Million |
€246.50 Million ≈ $288.18 Million |
+41.39pp |
| 2021-12-31 | 31.27% | €45.87 Million ≈ $53.63 Million |
€146.72 Million ≈ $171.53 Million |
-14.86pp |
| 2020-12-31 | 46.13% | €154.01 Million ≈ $180.06 Million |
€333.87 Million ≈ $390.33 Million |
+2.02pp |
| 2019-12-31 | 44.11% | €135.37 Million ≈ $158.27 Million |
€306.90 Million ≈ $358.80 Million |
+0.46pp |
| 2018-12-31 | 43.65% | €102.47 Million ≈ $119.79 Million |
€234.76 Million ≈ $274.45 Million |
-50.59pp |
| 2017-12-31 | 94.23% | €235.86 Million ≈ $275.74 Million |
€250.28 Million ≈ $292.61 Million |
+57.60pp |
| 2016-12-31 | 36.64% | €116.20 Million ≈ $135.85 Million |
€317.16 Million ≈ $370.79 Million |
+36.23pp |
| 2013-12-31 | 0.41% | €345.41K ≈ $403.82K |
€84.80 Million ≈ $99.14 Million |
-0.31pp |
| 2009-12-31 | 0.72% | €49.00K ≈ $57.29K |
€6.79 Million ≈ $7.94 Million |
-0.51pp |
| 2008-12-31 | 1.23% | €49.00K ≈ $57.29K |
€3.98 Million ≈ $4.66 Million |
+0.61pp |
| 2007-12-31 | 0.63% | €49.00K ≈ $57.29K |
€7.84 Million ≈ $9.16 Million |
-- |
About DBV Technologies S.A.
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. The company's product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of i… Read more